How to report and discuss ADME data in medicinal chemistry publications: in vitro data or in vivo extrapolations?

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Future Medicinal Chemistry

• Publication date

  2015-03-31

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.4155/fmc.14.165PMID 25826359
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Investigation of the prerequisites for the optimization of specific plasma protein binding as a strategy for the reduction of first-pass hepatic metabolism

  2015cited by this paper
• In vitro–in vivo extrapolation (IVIVE) for predicting human intestinal absorption and first-pass elimination of drugs: principles and applications

  2014cited by this paper
• Fundamentals of antimicrobial pharmacokinetics and pharmacodynamics

  2014cited by this paper
• Visualization of Plasma and Tissue Binding Using Dose Fractions Parameter

  2014cited by this paper
• In vitro-in vivo extrapolation method to predict human renal clearance of drugs.

  2014cited by this paper
• Lead optimization of 1,4-azaindoles as antimycobacterial agents.

  2014cited by this paper
• Physiologically Based Pharmacokinetic Modelling of Drug Penetration Across the Blood–Brain Barrier—Towards a Mechanistic IVIVE-Based Approach

  2013cited by this paper
• Permeability diagnosis model in drug discovery: a diagnostic tool to identify the most influencing properties for gastrointestinal permeability.

  2013cited by this paper
• Bioavailability: A pharmaceutical review

  2013cited by this paper
• Discovery of 2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile (perampanel): a novel, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid (AMPA) receptor antagonist.

  2012cited by this paper
• The determination and interpretation of the therapeutic index in drug development

  2012cited by this paper
• Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies

  2012cited by this paper
• Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results

  2012cited by this paper
• PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.

  2011cited by this paper
• PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasets.

  2011cited by this paper
• Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.

  2011cited by this paper
• A REVIEW ON: SUSTAINED RELEASED TECHNOLOGY

  2011cited by this paper
• PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution.

  2011cited by this paper
• ON : SUSTAINED RELEASED TECHNOLOGY

  2011cited by this paper
• PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance.

  2011cited by this paper
• PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach.

  2011cited by this paper
• Controversies in allometric scaling for predicting human drug clearance: an historical problem and reflections on what works and what does not.

  2011cited by this paper
• Productivity Shortfalls in Drug Discovery: Contributions from the Preclinical Sciences?

  2011cited by this paper
• Use of the Øie-Tozer Model in Understanding Mechanisms and Determinants of Drug Distribution

  2010cited by this paper
• Prediction of Vss from In Vitro Tissue-Binding Studies

  2010cited by this paper
• Species differences in pharmacokinetics and pharmacodynamics.

  2010cited by this paper
• Drug discovery in academia: the third way?

  2010cited by this paper
• The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery

  2010cited by this paper
• Impact of input parameters on the prediction of hepatic plasma clearance using the well-stirred model.

  2010cited by this paper
• Use of intrinsic clearance for prediction of human hepatic clearance

  2010cited by this paper
• Oral controlled release formulation design and drug delivery : theory to practice

  2010cited by this paper
• The 'free drug hypothesis' : fact or fiction?

  2008cited by this paper
• Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization

  2008cited by this paper
• Factors affecting therapeutic compliance: A review from the patient’s perspective

  2008cited by this paper
• Relationship between daily dose of oral medications and idiosyncratic drug‐induced liver injury: Search for signals

  2008cited by this paper
• Towards Quantitative Prediction of Oral Drug Absorption

  2008cited by this paper
• ADME Evaluation in Drug Discovery, 7. Prediction of Oral Absorption by Correlation and Classification

  2007cited by this paper
• Pharmaceutical Product Development : In Vitro-In Vivo Correlation

  2007cited by this paper
• Estimation of volume of distribution in humans from high throughput HPLC-based measurements of human serum albumin binding and immobilized artificial membrane partitioning.

  2006cited by this paper
• The road map to oral bioavailability: an industrial perspective

  2006cited by this paper
• THE BINDING OF DRUGS TO HEPATOCYTES AND ITS RELATIONSHIP TO PHYSICOCHEMICAL PROPERTIES

  2005cited by this paper
• A comprehensive listing of bioactivation pathways of organic functional groups.

  2005cited by this paper
• Predicting in vivo drug interactions from in vitro drug discovery data

  2005cited by this paper
• Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability

  2004cited by this paper
• Comparison of the Use of Liver Models for Predicting Drug Clearance Using in Vitro Kinetic Data from Hepatic Microsomes and Isolated Hepatocytes

  2004cited by this paper
• Plasma terminal half-life.

  2004cited by this paper
• In vitro-in vivo extrapolation: estimation of human serum concentrations of chemicals equivalent to cytotoxic concentrations in vitro.

  2003cited by this paper
• Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling

  2003cited by this paper
• How predictive is PK/PD for antibacterial agents?

  2002cited by this paper
• Molecular properties that influence the oral bioavailability of drug candidates.

  2002cited by this paper
• ADME evaluation in drug discovery

  2002cited by this paper
• The Integration of Four Major Determinants of Antibiotic Action: Bactericidal Activity, Postantibiotic Effect, Susceptibility, and Pharmacokinetics

  2002cited by this paper
• Pharmacodynamics of Antiinfective Therapy: Taking What We Know to the Patient's Bedside

  2001cited by this paper
• What Do We Really Know About Antibiotic Pharmacodynamics?

  2001cited by this paper
• A systematic review of the associations between dose regimens and medication compliance.

  2001cited by this paper
• Rapid-gradient HPLC method for measuring drug interactions with immobilized artificial membrane: comparison with other lipophilicity measures.

  2000cited by this paper
• Management of Narrow Therapeutic Index Drugs

  1999cited by this paper
• New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system.

  1999cited by this paper
• Polar Molecular Surface Properties Predict the Intestinal Absorption of Drugs in Humans

  1997cited by this paper
• Correlation of drug absorption with molecular surface properties.

  1996cited by this paper
• Interpatient variability in bioavailability is related to the extent of absorption: Implications for bioavailability and bioequivalence studies

  1996cited by this paper
• Multiple dose regimens. Impact on compliance.

  1995cited by this paper
• Structure-pharmacokinetic relationships among the barbiturates in the rat.

  1983cited by this paper
• Quantitative structure-pharmacokinetic relationships and drug design.

  1981cited by this paper
• Effect of altered plasma protein binding on apparent volume of distribution.

  1979cited by this paper
• FACTORS AFFECTING DRUG METABOLISM

  1971cited by this paper
• Toxicity, the Therapeutic Index, and the Ranking of Drugs

  1964cited by this paper

• Automatically updating predictive modeling workflows support decision-making in drug design.

  2016cites this paper